This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in BJP
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by ALMOND, S.
Right arrow Articles by BRUGHA, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ALMOND, S.
Right arrow Articles by BRUGHA, T.
The British Journal of Psychiatry (2004) 184: 346-351
© 2004 The Royal College of Psychiatrists

Relapse in schizophrenia: costs, clinical outcomes and quality of life

STEPHEN ALMOND, PhD

LSE Health and Social Care, London School of Economics and Political Science, London

MARTIN KNAPP, PhD

London School of Economics, and Institute of Psychiatry, London, UK

CLEMENT FRANCOIS and MONDHER TOUMI, PhD

Lundbeck SA, Paris, France

TRAOLACH BRUGHA, PhD

Section of Social and Epidemiological Psychiatry, Department of Psychiatry, University of Leicester, Leicester, UK

Correspondence: Professor Martin Knapp, PSSRU, LSE Health and Social Care, London School of Economics and Political Science, Houghton Street, London WC2A 2AE, UK. E-mail: m.knapp{at}lse.ac.uk

Declaration of interest None. Funding detailed in Acknowledgements.

Background Relapse is one of the most costly aspects of schizophrenia.

Aims To compare costs, clinical outcomes and quality of life for patients who experienced relapse in schizophrenia with a control group who did not relapse.

Method Patients were randomly selected from current psychiatric case-loads drawn from urban and suburban areas of Leicester. Differences in costs and outcomes by relapse status in the previous 6 months were examined using parametric and non-parametric tests, and multivariate analysis was used to examine factors associated with relapse and costs.

Results Costs for the patients who relapsed were over four times higher than those for the non-relapse group. There were few statistically significant differences in clinical and quality of life measures by relapse status. Multivariate analyses suggested some significant correlates of relapse and costs.

Conclusions The higher costs associated with relapse will be of interest to policy-makers who face difficultchoices concerning new but more expensive treatments for patients with schizophrenia.


Related articles in BJP:

Highlights of this issue
ELIZABETH WALSH
BJP 2004 184: 287-a15-298-a15. [Full Text]  



This article has been cited by other articles:


Home page
 Schizophr BullHome page
M. Alvarez-Jimenez, A. G. Parker, S. E. Hetrick, P. D. McGorry, and J. F. Gleeson
Preventing the Second Episode: A Systematic Review and Meta-analysis of Psychosocial and Pharmacological Trials in First-Episode psychosis
Schizophr Bull, November 9, 2009; (2009) sbp129v1.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
N. J. K. Breitborde, S. W. Woods, and V. H. Srihari
Multifamily Psychoeducation for First-Episode Psychosis: A Cost-Effectiveness Analysis
Psychiatr Serv, November 1, 2009; 60(11): 1477 - 1483.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
D. Wade, S. Harrigan, J. Edwards, P. M. Burgess, G. Whelan, and P. D. McGorry
Substance misuse in first-episode psychosis: 15-month prospective follow-up study
The British Journal of Psychiatry, September 1, 2006; 189(3): 229 - 234.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
W. Kissling, S. Heres, K. Lloyd, E. Sacchetti, P. Bouhours, R. Medori, and P. M. Llorca
Direct transition to long-acting risperidone - analysis of long-term efficacy
J Psychopharmacol, September 1, 2005; 19(5_suppl): 15 - 21.
[Abstract] [PDF]